A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentations have concluded.

Posters presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference highlight the complex care ...

Presentation: First Report of Phase Ib/2a Study Evaluating Safety and Early Efficacy of TN-201, an Adeno-Associated Virus Serotype 9 Gene Replacement Therapy, in Adults with MYBPC3 -Associated ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral ...

Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic ...

Pittsburg State University will host its first-ever AI symposium, AI in Academia and the Workforce: Exploring the Impact and Implications, on Monday, April 22, from 3 to 6 p.m. in the Overman Student ...

Dr. Laila El-Khattabi (Sorbonne University Hospitals and the Brain Institute, Paris, France) will share results from the CHROMAPS project, a multi-institutional European collaboration utilizing OGM to ...

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to ...

Keynote to Be Delivered by Dennis Lentz, Chief Digital Officer and Member of the Managing Board, Heidelberg Materials OTTAWA, ONTARIO / ACCESS Newswire / March 18, 2025 / Giatec®, a global leader in c ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...